SecBot SecBot
8-K ·Filed Feb 25, 2026

HCA

HCA Healthcare, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed8mo ago SEC0001193125-26-071880
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor HCA's 2026 EBITDA performance and quality metrics, as these will determine executive compensation payouts. The board retirement is routine and unlikely to affect governance or strategy.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$525.78
T+0 close · Feb 25, 2026 · via day close
Latest settled
−25.34%
T+60 · $392.56
Vs SPY
−33.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $525.78entry
  2. T+1 · 9mo ago +0.21%α +0.66% · $526.87
  3. T+5 · 9mo ago +1.37%α +2.50% · $532.98
  4. T+20 · 8mo ago −8.75%α −2.35% · $479.78
  5. T+60 · 6mo ago −25.34%α −33.09% · $392.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HCA Healthcare adopted its 2026 Executive Officer Performance Excellence Program (PEP), establishing cash-based incentive awards for executives tied to EBITDA (80%) and quality metrics (20%). The filing also announced the retirement of board member Robert J. Dennis effective April 23, 2026. No financial results or material operational changes were disclosed.

Key Facts

  • HCA adopted the 2026 Executive Officer Performance Excellence Program (PEP) on February 24, 2026
  • PEP awards are cash-based and tied to 80% EBITDA targets and 20% quality metrics (infections, complications, care experience)
  • Target award opportunities: 175% of base salary for CEO Samuel Hazen, 125% for CFO Michael Marks and COO Jon Foster, 100% for other named executives
  • No payment is made for quality metrics if actual EBITDA is below 90% of target
  • Board member Robert J. Dennis will retire effective April 23, 2026, after not standing for re-election

Financial Impact

No immediate financial impact disclosed; potential future cash compensation expense tied to 2026 performance

compensation expensecash flow from operations

Risk Factors

  • Executive compensation could increase significantly if EBITDA and quality targets are exceeded
  • No quality payouts if EBITDA falls below 90% of target, creating misalignment risk in challenging financial conditions

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071880
Document: d945112dex101.htm0001193125-26-071880
Document: 0001193125-26-071880-index-headers.html0001193125-26-071880
Document: 0001193125-26-071880-index.html0001193125-26-071880
Document: 0001193125-26-071880.txt0001193125-26-071880

US Market Status

Market Closed · Opens in 7h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026